BioNTech and Australia’s State of Victoria Form Strategic

• BioNTech and Australia’s State of Victoria will establish an mRNA research and innovation center to strengthen translational research for innovative medicines from discovery to delivery
• As part of the partnership, BioNTech is committed to building a BioNTainer^® facility for end-to-end clinical scale manufacturing of mRNA-based products and candidates in Melbourne
• BioNTech plans to further expand its clinical development capabilities in Australia and evaluate the testing of additional clinical cancer product candidates, including the autologous CAR-T cell therapy candidate BNT211, in addition to two Phase 2 candidates currently being tested in Australia 

MELBOURNE, Australia, October 7, 2022 —BioNTech SE (Nasdaq: BNTX) today announced that it has agreed a Letter of Intent with the State of Victoria in Australia on a strategic partnership between the State and BioNTech to collaborate on the research and development of potential mRNA-based vaccines and therapies. As part of the partnership, the parties will establish a research and innovation center in Melbourne to facilitate the transition of encouraging academic research into clinical development. BioNTech plans to set up a clinical scale end-to-end mRNA manufacturing facility based on its BioNTainer solution in Melbourne with the aim of supporting the design, manufacture and clinical testing of product candidates. Part of BioNTech’s global network, the facility is expected to attract interest from researchers locally, regionally and globally.

“Science and innovation can only make a difference if it is applied outside of the laboratories and reaches people worldwide. This partnership is a major step forward to enable access to mRNA technology and promote collaborations in the Asia-Pacific region,” said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Australia provides excellent academic research, and we are looking forward to collaborating with world-class scientists and researchers…